

**NEWS RELEASE
FOR IMMEDIATE RELEASE**

Company Contact:

Anthony J. Simonetta
Chief Financial Officer
(302) 456-6789
www.sdix.com

Investor Contact:

Hayden Communications
Brett Maas (brett@haydenir.com)
Matt Hayden (matt@haydenir.com)
(843) 272-4653

SDI's *Microtox*® Bioassay Technology Approved by Department of Homeland Security

Added to "Approved Products List for Homeland Security"

NEWARK, Del., February 14, 2006 - Strategic Diagnostics Inc. (Nasdaq: SDIX) – a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, announced today that its *Microtox*® Bioassay technology was awarded the Designation and Certification as an 'Approved Product for Homeland Security' under the Support Anti-Terrorism by Fostering Effective Technologies Act of 2002 (the SAFETY ACT), by the Department of Homeland Security, or DHS. Accordingly, *Microtox*® has been placed on the "Approved Products List for Homeland Security."

Matthew Knight, President and CEO of Strategic Diagnostics Inc., commented, "*Microtox*® is the water industry bioassay standard for rapid detection of toxins, as it detects toxicity over a broad spectrum of more than 2,000 biological and chemical toxins. We are pleased to play a role in the Homeland Security effort, and remain prepared to assist local, state and federal law enforcement and homeland security personnel in maintaining water safety for all Americans. This designation and certification is the result of many months of evaluation and clearly demonstrates the strength of the *Microtox*® technology. We believe this will further raise awareness to the application of the technology to enhance not just the quality, but also equally important, the security of drinking water supplies."

The SAFETY ACT legislation was designed to encourage the development and rapid deployment of life-saving anti-terrorism technologies by providing manufacturers or sellers with limited risk to legal liability. It was also designed to harness the nation's scientific and technological resources to provide federal, state, and local officials with the technology and capabilities to protect the United States from terrorist acts. One area of focus for DHS is catastrophic terrorism threats to the nation's security that could result in large-scale loss of life and major economic impact. The SAFETY ACT fosters research of technologies to counter threats both by evolutionary improvements to current capabilities and development of revolutionary, new capabilities. As a biosensor-based method for the detection of toxic compounds, which include toxic industrial chemicals and heavy metals, in water and other matrices, the *Microtox*® Bioassay technology is ideally suited to meet the anti-terrorism initiative objectives of DHS.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

#